DTP Pharmacies March On In China: Pharma Ignores At Its Own Risk
A shift in dispensing from hospitals to external pharmacies has led to predictions that the direct-to-patient sales model will be big in China. But only those with the right partnerships and expertise will reap the benefits, leading pharmacy chain executives told a recent conference.
You may also be interested in...
Tough new rules from China’s State Council have put the country’s one million medical reps into limbo as their employers scrabble to get to grips with broad curbs on sales activities.
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.